Literature DB >> 22494971

Ras stabilization through aberrant activation of Wnt/β-catenin signaling promotes intestinal tumorigenesis.

Woo-Jeong Jeong1, Juyong Yoon, Jong-Chan Park, Soung-Hoon Lee, Seung-Hoon Lee, Saluja Kaduwal, Hoguen Kim, Jong-Bok Yoon, Kang-Yell Choi.   

Abstract

Although the guanosine triphosphate/guanosine diphosphate loading switch is a major regulatory mechanism that controls the activity of the guanosine triphosphatase Ras, we report a distinct mechanism for regulating Ras activity through phosphorylation-mediated degradation and describe the role of this second regulatory mechanism in the suppression of cellular transformation and tumors induced by Ras mutations. We found that negative regulators of Wnt/β-catenin signaling contributed to the polyubiquitin-dependent degradation of Ras after its phosphorylation by glycogen synthase kinase 3β (GSK3β) and the subsequent recruitment of β-TrCP-E3 ligase. We found a positive association between tumorigenesis and Ras stabilization resulting from the aberrant activation of Wnt/β-catenin signaling in adenomas from two mouse models of colon cancer, human colonic tumors from various stages, and colon polyps of patients with familial adenomatous polyposis. Our results indicated that GSK3β plays an essential role in Ras degradation and that inhibition of this degradation pathway by aberrant Wnt/β-catenin signaling may contribute to Ras-induced transformation in colorectal tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22494971     DOI: 10.1126/scisignal.2002242

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  79 in total

Review 1.  Posttranslational Modifications of RAS Proteins.

Authors:  Ian Ahearn; Mo Zhou; Mark R Philips
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

2.  KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.

Authors:  Dana Rabara; Timothy H Tran; Srisathiyanarayanan Dharmaiah; Robert M Stephens; Frank McCormick; Dhirendra K Simanshu; Matthew Holderfield
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

Review 3.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 4.  Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch.

Authors:  Fred E Bertrand; C William Angus; William J Partis; George Sigounas
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

5.  Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding.

Authors:  Pamela Y Ting; Christian W Johnson; Cong Fang; Xiaoqing Cao; Thomas G Graeber; Carla Mattos; John Colicelli
Journal:  FASEB J       Date:  2015-05-21       Impact factor: 5.191

Review 6.  Role of retinoids in the prevention and treatment of colorectal cancer.

Authors:  Catherine C Applegate; Michelle A Lane
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

7.  S-Palmitoylation of a Novel Site in the β2-Adrenergic Receptor Associated with a Novel Intracellular Itinerary.

Authors:  Naoko Adachi; Douglas T Hess; Precious McLaughlin; Jonathan S Stamler
Journal:  J Biol Chem       Date:  2016-08-01       Impact factor: 5.157

8.  Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.

Authors:  Hua Li; Mingjia Tan; Lijun Jia; Dongping Wei; Yongchao Zhao; Guoan Chen; Jie Xu; Lili Zhao; Dafydd Thomas; David G Beer; Yi Sun
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

Review 9.  The way Wnt works: components and mechanism.

Authors:  Kenyi Saito-Diaz; Tony W Chen; Xiaoxi Wang; Curtis A Thorne; Heather A Wallace; Andrea Page-McCaw; Ethan Lee
Journal:  Growth Factors       Date:  2012-12-21       Impact factor: 2.511

Review 10.  Genomic insights into WNT/β-catenin signaling.

Authors:  Joseph Rosenbluh; Xiaoxing Wang; William C Hahn
Journal:  Trends Pharmacol Sci       Date:  2013-12-20       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.